| Code | 1556F | ||||||||||
| MA number | 16/0335/25-S | ||||||||||
| Product Form: | tbl flm 28x15 mg (blis.PVC/PVDC/Al) | ||||||||||
| MA Status: | R - Valid Marketing Authorisation | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | AS Olpha, Latvia | ||||||||||
| Therapeutic Class: | 16 - ANTICOAGULANTIA (FIBRINOLYTICA, ANTIFIBRINOL.) | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 24 | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 22.10.2025 |
| Validity: | 22.10.2030 |
| Pediatric indication: | Yes |
| Pediatric posology: | Yes |
| Pediatric warnings: | Yes |
| PIL: |
PIL_Rivaroxaban Olpha 15 mg; 20 mg filmom obalené tablety_10.2025.pdf
|
| SPC: |
SPC_Rivaroxaban Olpha 15 mg filmom obalené tablety_10.2025.pdf
|
| Safety feature | Yes |
| Data update: | 27.10.2025 |
